President Donald Trump has signed an executive order expanding federal research into psychedelic drugs and explore their use in controlled medical settings.
The order direct the Food and Drug Administration to issue new guidance for clinical trials involving substances such as psilocybin, ibogaine, LSD, and MDMA.
The podcast host Joe Rogan, who has long advocated for research into psychedelics, attended the signing ceremony.
Joe Rogan joins Trump in the Oval Office.
Let’s go.pic.twitter.com/HniutWdXeu
— Joe Rogan Podcast News (@joeroganhq)April 18, 2026
Such drugs are currently classified as Schedule I, meaning they are considered to have no accepted medical use and a high potential for abuse.
The administration believes in the potential role of these treatments in addressing post-traumatic stress disorder and other mental health conditions, particularly among military veterans.
The National Institutes of Health is also being tasked with supporting additional studies into the drugs.
President Trump is set to announce new efforts to boost research into psychedelics and potentially make the drugs available in controlled therapeutic environments, according to people who spoke on the condition of anonymity.https://t.co/WyMjovUHtd
Source: The Gateway Pundit
